Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients

Meeuwis, 2012, Anogenital malignancies in women after renal transplantation over 40 years in a single center, Transplantation, 93, 914, 10.1097/TP.0b013e318249b13d Park, 2011, Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients, World J Surg Oncol [Clinical Trial Comparative Study], 9, 72, 10.1186/1477-7819-9-72 Paternoster, 2008, Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients, Transplant Proc, 40, 1877, 10.1016/j.transproceed.2008.05.074 Patel, 2010, Human papillomavirus infection and anal dysplasia in renal transplant recipients, Br J Surg, 97, 1716, 10.1002/bjs.7218 Meeuwis, 2011, (Pre)malignancies of the female anogenital tract in renal transplant recipients, Transplantation, 91, 8, 10.1097/TP.0b013e3181fbd008 Mochizuki, 2012, Gene expression profile in the liver of Rana catesbeiana tadpoles exposed to low temperature in the presence of thyroid hormone, Biochem Biophys Res Commun, 420, 845, 10.1016/j.bbrc.2012.03.085 Kwak, 2009, Human papillomavirus infection in solid organ transplant recipients, Am J Transplant, 9, S151, 10.1111/j.1600-6143.2009.02906.x Dillner, 2010, Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, vaginal intraepithelial neoplasia, anogenital warts: Randomised controlled trial, BMJ, 341, c3493, 10.1136/bmj.c3493 Garland, 2007, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, N Engl J Med, 356, 1928, 10.1056/NEJMoa061760 2007, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, N Engl J Med, 356, 1915, 10.1056/NEJMoa061741 Wheeler, 2009, Human papillomavirus genotype distributions: Implications for vaccination and cancer screening in the United States, J Natl Cancer Inst, 101, 475, 10.1093/jnci/djn510 Valles, 2009, High prevalence of human papillomavirus infection in the female population of Guatemala, Int J Cancer, 125, 1161, 10.1002/ijc.24444 Smith, 2007, Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update, Int J Cancer, 121, 621, 10.1002/ijc.22527 Munoz, 2009, Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11 16, 18) recombinant vaccine in women aged 24–45 years: A randomised, double-blind trial, Lancet, 373, 1949, 10.1016/S0140-6736(09)60691-7 Avery, 2008, Update on immunizations in solid organ transplant recipients: What clinicians need to know, Am J Transplant, 8, 9, 10.1111/j.1600-6143.2007.02051.x Pastrana, 2004, Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18, Virology, 321, 205, 10.1016/j.virol.2003.12.027 Opalka, 2003, Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11 16, and 18 by a multiplexed luminex assay, Clin Diagn Lab Immunol, 10, 108 Villa, 2006, Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18, Vaccine, 24, 5571, 10.1016/j.vaccine.2006.04.068 Giuliano, 2011, Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males, N Engl J Med, 364, 401, 10.1056/NEJMoa0909537 Manuel, 2011, Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients, J Heart Lung Transplant, 30, 679, 10.1016/j.healun.2011.01.705 Birdwell, 2009, Decreased antibody response to influenza vaccination in kidney transplant recipients: A prospective cohort study, Am J Kidney Dis, 54, 112, 10.1053/j.ajkd.2008.09.023 Versluis, 1986, Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine, Transplantation, 42, 376, 10.1097/00007890-198610000-00009 2007, Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection, J Infect Dis, 196, 1438, 10.1086/522864 Wilkin, 2010, Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men, J Infect Dis, 202, 1246, 10.1086/656320 Levin, 2010, Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11 16, and 18) vaccine in HIV-infected children 7 to 12 years old, J Acquir Immune Defic Syndr, 55, 197, 10.1097/QAI.0b013e3181de8d26 Weinberg, 2012, Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children, J Infect Dis, 206, 1309, 10.1093/infdis/jis489 Einstein, 2009, Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years, Hum Vaccin, 5, 705, 10.4161/hv.5.10.9518 Einstein, 2011, Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years, Hum Vaccin, 7, 1359, 10.4161/hv.7.12.18282